Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Victoria Y. Strauss, Rachel Shaw, Pradeep S. Virdee, Christopher N. Hurt, Elizabeth Ward, Bethan Tranter, Neel Patel, John Bridgewater, Philip Parsons, Ganesh Radhakrishna, Eric O’Neill, David Sebag-Montefiore, Maria Hawkins, Pippa G. Corrie, Timothy Maughan, Somnath Mukherjee

ABSTRACT

BACKGROUND: Induction chemotherapy followed by chemoradiation is a treatment option for patients with locally advanced pancreatic cancer (LAPC). However, overall survival is comparable to chemotherapy alone and local progression occurs in nearly half of all patients, suggesting chemoradiation strategies should be optimised. SCALOP-2 is a randomised phase II trial testing the role of radiotherapy dose escalation and/or the addition of the radiosensitiser nelfinavir, following induction chemotherapy of gemcitabine and nab-paclitaxel (GEMABX). A safety run-in phase (stage 1) established the nelfinavir dose to administer with chemoradiation in the randomised phase (stage 2). METHODS: Patients with locally advanced, inoperable, non-metastatic pancreatic adenocarcinoma receive three cycles of induction GEMABX chemotherapy prior to radiological assessment. Those with stable/responding disease are eligible for further trial treatment. In Stage 1, participants received one further cycle of GEMABX followed by capecitabine-chemoradiation with escalating doses of nelfinavir in a rolling-six design. Stage 2 aims to register 262 and randomise 170 patients with responding/stable disease to one of five arms: capecitabine with high- (arms C + D) or standard-dose (arms A + B) radiotherapy with (arms A + C) or without (arms B + D) nelfinavir, or three more cycles of GEMABX (arm E). Participants allocated to the chemoradiation arms receive another cycle of GEMABX before chemoradiation begins. Co-primary outcomes are 12-month overall survival (radiotherapy dose-escalation question) and progression-free survival (nelfinavir question). Secondary outcomes include toxicity, quality of life, disease response rate, resection rate, treatment compliance, and CA19-9 response. SCALOP-2 incorporates a detailed radiotherapy quality assurance programme. DISCUSSION: SCALOP-2 aims to optimise chemoradiation in LAPC and incorporates a modern induction regimen. TRIAL REGISTRATION: Eudract No: 2013-004968-56; ClinicalTrials.gov : NCT02024009. More... »

PAGES

121

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-019-5307-z

DOI

http://dx.doi.org/10.1186/s12885-019-5307-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111916370

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30717707


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Centre for Statistics in Medicine, University of Oxford, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Strauss", 
        "givenName": "Victoria Y.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Oncology Clinical Trials Office, University of Oxford, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shaw", 
        "givenName": "Rachel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Centre for Statistics in Medicine, University of Oxford, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Virdee", 
        "givenName": "Pradeep S.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiff University", 
          "id": "https://www.grid.ac/institutes/grid.5600.3", 
          "name": [
            "Centre for Trials Research, Cardiff University, Cardiff, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hurt", 
        "givenName": "Christopher N.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bristol Royal Infirmary", 
          "id": "https://www.grid.ac/institutes/grid.418482.3", 
          "name": [
            "Clinical Trials and Evaluation Unit, Bristol Royal Infirmary, Bristol, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ward", 
        "givenName": "Elizabeth", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Velindre Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.470144.2", 
          "name": [
            "Pharmacy Department, Velindre Cancer Centre, Velindre NHS University Trust, Cardiff, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tranter", 
        "givenName": "Bethan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Churchill Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415719.f", 
          "name": [
            "Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Patel", 
        "givenName": "Neel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University College Hospital", 
          "id": "https://www.grid.ac/institutes/grid.439749.4", 
          "name": [
            "Department of Oncology, University College London Hospitals, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bridgewater", 
        "givenName": "John", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Velindre Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.470144.2", 
          "name": [
            "Cardiff NCRI RTTQA group, Department of Medical Physics, Velindre Cancer Centre, Cardiff, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Parsons", 
        "givenName": "Philip", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Christie Hospital NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.412917.8", 
          "name": [
            "Oncology Department, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Radhakrishna", 
        "givenName": "Ganesh", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Department of Oncology, University of Oxford, CRUK MRC Oxford Institute for Radiation Oncology, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "O\u2019Neill", 
        "givenName": "Eric", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University of Leeds, Leeds Cancer Centre, St James\u2019s University Hospital, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sebag-Montefiore", 
        "givenName": "David", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Department of Oncology, University of Oxford, CRUK MRC Oxford Institute for Radiation Oncology, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hawkins", 
        "givenName": "Maria", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Addenbrooke's Hospital", 
          "id": "https://www.grid.ac/institutes/grid.120073.7", 
          "name": [
            "Cambridge Cancer Centre, Addenbrooke\u2019s Hospital, Cambridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Corrie", 
        "givenName": "Pippa G.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Department of Oncology, University of Oxford, CRUK MRC Oxford Institute for Radiation Oncology, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maughan", 
        "givenName": "Timothy", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Department of Oncology, University of Oxford, CRUK MRC Oxford Institute for Radiation Oncology, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mukherjee", 
        "givenName": "Somnath", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-09-1324", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000642406"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-06-1239", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000833623"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.15.2355", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008041290"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-09-0657", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011022022"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2004.04.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012646128"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1748-717x-7-156", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013784022", 
          "https://doi.org/10.1186/1748-717x-7-156"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.radonc.2009.04.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014271047"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.17.7188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017430935"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.radonc.2016.03.021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017501197"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdn281", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019387985"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-05-1220", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022622708"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-08-0757", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026599802"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2012.02.051", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033040622"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.33.8038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034167619"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70021-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041381779"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pmed.1000267", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045271156"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2007.01.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046097055"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.12.7712", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046116901"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2003.11.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048100421"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2003.11.019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051174392"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2006.12.053", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052268854"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/cbt.7.5.5728", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072294963"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075125171", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.31.18_suppl.lba4003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083394061"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Induction chemotherapy followed by chemoradiation is a treatment option for patients with locally advanced pancreatic cancer (LAPC). However, overall survival is comparable to chemotherapy alone and local progression occurs in nearly half of all patients, suggesting chemoradiation strategies should be optimised. SCALOP-2 is a randomised phase II trial testing the role of radiotherapy dose escalation and/or the addition of the radiosensitiser nelfinavir, following induction chemotherapy of gemcitabine and nab-paclitaxel (GEMABX). A safety run-in phase (stage 1) established the nelfinavir dose to administer with chemoradiation in the randomised phase (stage 2).\nMETHODS: Patients with locally advanced, inoperable, non-metastatic pancreatic adenocarcinoma receive three cycles of induction GEMABX chemotherapy prior to radiological assessment. Those with stable/responding disease are eligible for further trial treatment. In Stage 1, participants received one further cycle of GEMABX followed by capecitabine-chemoradiation with escalating doses of nelfinavir in a rolling-six design. Stage 2 aims to register 262 and randomise 170 patients with responding/stable disease to one of five arms: capecitabine with high- (arms C\u2009+\u2009D) or standard-dose (arms A\u2009+\u2009B) radiotherapy with (arms A\u2009+\u2009C) or without (arms B\u2009+\u2009D) nelfinavir, or three more cycles of GEMABX (arm E). Participants allocated to the chemoradiation arms receive another cycle of GEMABX before chemoradiation begins. Co-primary outcomes are 12-month overall survival (radiotherapy dose-escalation question) and progression-free survival (nelfinavir question). Secondary outcomes include toxicity, quality of life, disease response rate, resection rate, treatment compliance, and CA19-9 response. SCALOP-2 incorporates a detailed radiotherapy quality assurance programme.\nDISCUSSION: SCALOP-2 aims to optimise chemoradiation in LAPC and incorporates a modern induction regimen.\nTRIAL REGISTRATION: Eudract No: 2013-004968-56; ClinicalTrials.gov : NCT02024009.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-019-5307-z", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine \u00b1 nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)", 
    "pagination": "121", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c54dadc216101b4b8d376c582dc8a1994bc1d0239c3cccc5ccb65077ebf747ff"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30717707"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-019-5307-z"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111916370"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-019-5307-z", 
      "https://app.dimensions.ai/details/publication/pub.1111916370"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000329_0000000329/records_74704_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12885-019-5307-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5307-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5307-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5307-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5307-z'


 

This table displays all metadata directly associated to this object as RDF triples.

255 TRIPLES      21 PREDICATES      53 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-019-5307-z schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N5153d7b94bd847e498c968f9579dfa17
4 schema:citation sg:pub.10.1186/1748-717x-7-156
5 https://app.dimensions.ai/details/publication/pub.1075125171
6 https://doi.org/10.1016/j.ijrobp.2003.11.003
7 https://doi.org/10.1016/j.ijrobp.2003.11.019
8 https://doi.org/10.1016/j.ijrobp.2004.04.004
9 https://doi.org/10.1016/j.ijrobp.2006.12.053
10 https://doi.org/10.1016/j.ijrobp.2007.01.005
11 https://doi.org/10.1016/j.ijrobp.2012.02.051
12 https://doi.org/10.1016/j.radonc.2009.04.015
13 https://doi.org/10.1016/j.radonc.2016.03.021
14 https://doi.org/10.1016/s1470-2045(13)70021-4
15 https://doi.org/10.1093/annonc/mdn281
16 https://doi.org/10.1158/0008-5472.can-05-1220
17 https://doi.org/10.1158/0008-5472.can-06-1239
18 https://doi.org/10.1158/0008-5472.can-08-0757
19 https://doi.org/10.1158/0008-5472.can-09-0657
20 https://doi.org/10.1158/1078-0432.ccr-09-1324
21 https://doi.org/10.1200/jco.2007.12.7712
22 https://doi.org/10.1200/jco.2007.15.2355
23 https://doi.org/10.1200/jco.2008.17.7188
24 https://doi.org/10.1200/jco.2010.33.8038
25 https://doi.org/10.1200/jco.2013.31.18_suppl.lba4003
26 https://doi.org/10.1371/journal.pmed.1000267
27 https://doi.org/10.4161/cbt.7.5.5728
28 schema:datePublished 2019-12
29 schema:datePublishedReg 2019-12-01
30 schema:description BACKGROUND: Induction chemotherapy followed by chemoradiation is a treatment option for patients with locally advanced pancreatic cancer (LAPC). However, overall survival is comparable to chemotherapy alone and local progression occurs in nearly half of all patients, suggesting chemoradiation strategies should be optimised. SCALOP-2 is a randomised phase II trial testing the role of radiotherapy dose escalation and/or the addition of the radiosensitiser nelfinavir, following induction chemotherapy of gemcitabine and nab-paclitaxel (GEMABX). A safety run-in phase (stage 1) established the nelfinavir dose to administer with chemoradiation in the randomised phase (stage 2). METHODS: Patients with locally advanced, inoperable, non-metastatic pancreatic adenocarcinoma receive three cycles of induction GEMABX chemotherapy prior to radiological assessment. Those with stable/responding disease are eligible for further trial treatment. In Stage 1, participants received one further cycle of GEMABX followed by capecitabine-chemoradiation with escalating doses of nelfinavir in a rolling-six design. Stage 2 aims to register 262 and randomise 170 patients with responding/stable disease to one of five arms: capecitabine with high- (arms C + D) or standard-dose (arms A + B) radiotherapy with (arms A + C) or without (arms B + D) nelfinavir, or three more cycles of GEMABX (arm E). Participants allocated to the chemoradiation arms receive another cycle of GEMABX before chemoradiation begins. Co-primary outcomes are 12-month overall survival (radiotherapy dose-escalation question) and progression-free survival (nelfinavir question). Secondary outcomes include toxicity, quality of life, disease response rate, resection rate, treatment compliance, and CA19-9 response. SCALOP-2 incorporates a detailed radiotherapy quality assurance programme. DISCUSSION: SCALOP-2 aims to optimise chemoradiation in LAPC and incorporates a modern induction regimen. TRIAL REGISTRATION: Eudract No: 2013-004968-56; ClinicalTrials.gov : NCT02024009.
31 schema:genre research_article
32 schema:inLanguage en
33 schema:isAccessibleForFree true
34 schema:isPartOf N6e29095281174cbe89e2f46d33442134
35 N86d11d57fe8444b7a5f648e2b97cf55e
36 sg:journal.1024632
37 schema:name Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)
38 schema:pagination 121
39 schema:productId N67c8c34553fc42f0bb36f8e2390a9a21
40 N7261fca31a1b4b9f8fb73e79d39f9acd
41 N8304247f7deb49f19f02a791c7568a3a
42 N8860e75d60c64f4db7e2117c5c94a42d
43 Nf435687f437b408dab11162c8b0976e8
44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111916370
45 https://doi.org/10.1186/s12885-019-5307-z
46 schema:sdDatePublished 2019-04-11T09:01
47 schema:sdLicense https://scigraph.springernature.com/explorer/license/
48 schema:sdPublisher Na4792bab10c0471a8f684d22303452ef
49 schema:url https://link.springer.com/10.1186%2Fs12885-019-5307-z
50 sgo:license sg:explorer/license/
51 sgo:sdDataset articles
52 rdf:type schema:ScholarlyArticle
53 N0f94895351474ed786e115b9ad38266b rdf:first Nd7dc7a0af4194d9993ab3e5317422c53
54 rdf:rest Ne44b1eef8c7e4908ab5d5c303b895102
55 N1374be28b9fb4ed89d79deb8f881ac42 rdf:first N1d96d721815649a7b30387dfdd90ddc2
56 rdf:rest Nacb1a50ad2d54c28b9b97df691193150
57 N19cb50f798f249b7bf3696978ba3ac13 rdf:first Nddd487ac4e124289ab1193a06002ce64
58 rdf:rest N40c4cc1315f74472be1a8781c1c6b95a
59 N1d96d721815649a7b30387dfdd90ddc2 schema:affiliation https://www.grid.ac/institutes/grid.470144.2
60 schema:familyName Parsons
61 schema:givenName Philip
62 rdf:type schema:Person
63 N1efba86dc4e24b87b95e0e0f9527ab99 schema:affiliation https://www.grid.ac/institutes/grid.418482.3
64 schema:familyName Ward
65 schema:givenName Elizabeth
66 rdf:type schema:Person
67 N208f784bc908449281a9fdd4e0e24e77 schema:affiliation N28d842b1f88741fc8c2b2118be7d79ec
68 schema:familyName Sebag-Montefiore
69 schema:givenName David
70 rdf:type schema:Person
71 N24633b747d114749a6ea1cfe7c564167 rdf:first Ne3ccad6e1e6149228d8cebc1801719fe
72 rdf:rest rdf:nil
73 N2522facefde9426eb93ac36335e0225c schema:affiliation https://www.grid.ac/institutes/grid.4991.5
74 schema:familyName Shaw
75 schema:givenName Rachel
76 rdf:type schema:Person
77 N28d842b1f88741fc8c2b2118be7d79ec schema:name University of Leeds, Leeds Cancer Centre, St James’s University Hospital, Leeds, UK
78 rdf:type schema:Organization
79 N2d74f45ad3a2485a85e402c013d50874 rdf:first N8e3ae9144bdc435b86c216fb0aa5b30b
80 rdf:rest Nc107ea895ddb421eaabc16a4118b21d8
81 N3c7d8b958edf4e619360d535a5b1e016 schema:affiliation https://www.grid.ac/institutes/grid.120073.7
82 schema:familyName Corrie
83 schema:givenName Pippa G.
84 rdf:type schema:Person
85 N40c4cc1315f74472be1a8781c1c6b95a rdf:first N3c7d8b958edf4e619360d535a5b1e016
86 rdf:rest Nb6108b1140634ac99080709a8ccbebf0
87 N49622c4827a24a8ebd5c7b57ef59d362 schema:affiliation https://www.grid.ac/institutes/grid.4991.5
88 schema:familyName Strauss
89 schema:givenName Victoria Y.
90 rdf:type schema:Person
91 N5153d7b94bd847e498c968f9579dfa17 rdf:first N49622c4827a24a8ebd5c7b57ef59d362
92 rdf:rest N8365d57ec63d44d5bff25b326f969838
93 N550cf0dd0ec4476baa0eddc61961e4af rdf:first Nc6db36706cf5409ca7ba55d13bf9f135
94 rdf:rest N2d74f45ad3a2485a85e402c013d50874
95 N67abb6eab69745518771e0b3c5d9e013 schema:affiliation https://www.grid.ac/institutes/grid.412917.8
96 schema:familyName Radhakrishna
97 schema:givenName Ganesh
98 rdf:type schema:Person
99 N67c8c34553fc42f0bb36f8e2390a9a21 schema:name dimensions_id
100 schema:value pub.1111916370
101 rdf:type schema:PropertyValue
102 N6e29095281174cbe89e2f46d33442134 schema:volumeNumber 19
103 rdf:type schema:PublicationVolume
104 N7261fca31a1b4b9f8fb73e79d39f9acd schema:name doi
105 schema:value 10.1186/s12885-019-5307-z
106 rdf:type schema:PropertyValue
107 N8212737e19674a20b64c4992cdfafbf9 rdf:first N208f784bc908449281a9fdd4e0e24e77
108 rdf:rest N19cb50f798f249b7bf3696978ba3ac13
109 N8226b16c5ba644d495b92261719b88c1 schema:affiliation https://www.grid.ac/institutes/grid.4991.5
110 schema:familyName O’Neill
111 schema:givenName Eric
112 rdf:type schema:Person
113 N8304247f7deb49f19f02a791c7568a3a schema:name nlm_unique_id
114 schema:value 100967800
115 rdf:type schema:PropertyValue
116 N8365d57ec63d44d5bff25b326f969838 rdf:first N2522facefde9426eb93ac36335e0225c
117 rdf:rest N550cf0dd0ec4476baa0eddc61961e4af
118 N86d11d57fe8444b7a5f648e2b97cf55e schema:issueNumber 1
119 rdf:type schema:PublicationIssue
120 N8860e75d60c64f4db7e2117c5c94a42d schema:name readcube_id
121 schema:value c54dadc216101b4b8d376c582dc8a1994bc1d0239c3cccc5ccb65077ebf747ff
122 rdf:type schema:PropertyValue
123 N8e3ae9144bdc435b86c216fb0aa5b30b schema:affiliation https://www.grid.ac/institutes/grid.5600.3
124 schema:familyName Hurt
125 schema:givenName Christopher N.
126 rdf:type schema:Person
127 N9f6ed31a6192480db9c7732e67858f9d schema:affiliation https://www.grid.ac/institutes/grid.470144.2
128 schema:familyName Tranter
129 schema:givenName Bethan
130 rdf:type schema:Person
131 Na4792bab10c0471a8f684d22303452ef schema:name Springer Nature - SN SciGraph project
132 rdf:type schema:Organization
133 Nacb1a50ad2d54c28b9b97df691193150 rdf:first N67abb6eab69745518771e0b3c5d9e013
134 rdf:rest Nc902e8ee585744648b1bd985a365f58f
135 Nb6108b1140634ac99080709a8ccbebf0 rdf:first Nc705987362a444df81fd44aa753afafc
136 rdf:rest N24633b747d114749a6ea1cfe7c564167
137 Nc107ea895ddb421eaabc16a4118b21d8 rdf:first N1efba86dc4e24b87b95e0e0f9527ab99
138 rdf:rest Nec79e7772f6646b794e065014a683067
139 Nc6db36706cf5409ca7ba55d13bf9f135 schema:affiliation https://www.grid.ac/institutes/grid.4991.5
140 schema:familyName Virdee
141 schema:givenName Pradeep S.
142 rdf:type schema:Person
143 Nc705987362a444df81fd44aa753afafc schema:affiliation https://www.grid.ac/institutes/grid.4991.5
144 schema:familyName Maughan
145 schema:givenName Timothy
146 rdf:type schema:Person
147 Nc902e8ee585744648b1bd985a365f58f rdf:first N8226b16c5ba644d495b92261719b88c1
148 rdf:rest N8212737e19674a20b64c4992cdfafbf9
149 Nd7dc7a0af4194d9993ab3e5317422c53 schema:affiliation https://www.grid.ac/institutes/grid.415719.f
150 schema:familyName Patel
151 schema:givenName Neel
152 rdf:type schema:Person
153 Nddd487ac4e124289ab1193a06002ce64 schema:affiliation https://www.grid.ac/institutes/grid.4991.5
154 schema:familyName Hawkins
155 schema:givenName Maria
156 rdf:type schema:Person
157 Ne3ccad6e1e6149228d8cebc1801719fe schema:affiliation https://www.grid.ac/institutes/grid.4991.5
158 schema:familyName Mukherjee
159 schema:givenName Somnath
160 rdf:type schema:Person
161 Ne44b1eef8c7e4908ab5d5c303b895102 rdf:first Nf7bb0e1af08642349d57e006535d71d0
162 rdf:rest N1374be28b9fb4ed89d79deb8f881ac42
163 Nec79e7772f6646b794e065014a683067 rdf:first N9f6ed31a6192480db9c7732e67858f9d
164 rdf:rest N0f94895351474ed786e115b9ad38266b
165 Nf435687f437b408dab11162c8b0976e8 schema:name pubmed_id
166 schema:value 30717707
167 rdf:type schema:PropertyValue
168 Nf7bb0e1af08642349d57e006535d71d0 schema:affiliation https://www.grid.ac/institutes/grid.439749.4
169 schema:familyName Bridgewater
170 schema:givenName John
171 rdf:type schema:Person
172 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
173 schema:name Medical and Health Sciences
174 rdf:type schema:DefinedTerm
175 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
176 schema:name Oncology and Carcinogenesis
177 rdf:type schema:DefinedTerm
178 sg:journal.1024632 schema:issn 1471-2407
179 schema:name BMC Cancer
180 rdf:type schema:Periodical
181 sg:pub.10.1186/1748-717x-7-156 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013784022
182 https://doi.org/10.1186/1748-717x-7-156
183 rdf:type schema:CreativeWork
184 https://app.dimensions.ai/details/publication/pub.1075125171 schema:CreativeWork
185 https://doi.org/10.1016/j.ijrobp.2003.11.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048100421
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1016/j.ijrobp.2003.11.019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051174392
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1016/j.ijrobp.2004.04.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012646128
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1016/j.ijrobp.2006.12.053 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052268854
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1016/j.ijrobp.2007.01.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046097055
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1016/j.ijrobp.2012.02.051 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033040622
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1016/j.radonc.2009.04.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014271047
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1016/j.radonc.2016.03.021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017501197
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1016/s1470-2045(13)70021-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041381779
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1093/annonc/mdn281 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019387985
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1158/0008-5472.can-05-1220 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022622708
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1158/0008-5472.can-06-1239 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000833623
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1158/0008-5472.can-08-0757 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026599802
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1158/0008-5472.can-09-0657 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011022022
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1158/1078-0432.ccr-09-1324 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000642406
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1200/jco.2007.12.7712 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046116901
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1200/jco.2007.15.2355 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008041290
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1200/jco.2008.17.7188 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017430935
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1200/jco.2010.33.8038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034167619
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1200/jco.2013.31.18_suppl.lba4003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083394061
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1371/journal.pmed.1000267 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045271156
226 rdf:type schema:CreativeWork
227 https://doi.org/10.4161/cbt.7.5.5728 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072294963
228 rdf:type schema:CreativeWork
229 https://www.grid.ac/institutes/grid.120073.7 schema:alternateName Addenbrooke's Hospital
230 schema:name Cambridge Cancer Centre, Addenbrooke’s Hospital, Cambridge, UK
231 rdf:type schema:Organization
232 https://www.grid.ac/institutes/grid.412917.8 schema:alternateName Christie Hospital NHS Foundation Trust
233 schema:name Oncology Department, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, UK
234 rdf:type schema:Organization
235 https://www.grid.ac/institutes/grid.415719.f schema:alternateName Churchill Hospital
236 schema:name Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK
237 rdf:type schema:Organization
238 https://www.grid.ac/institutes/grid.418482.3 schema:alternateName Bristol Royal Infirmary
239 schema:name Clinical Trials and Evaluation Unit, Bristol Royal Infirmary, Bristol, UK
240 rdf:type schema:Organization
241 https://www.grid.ac/institutes/grid.439749.4 schema:alternateName University College Hospital
242 schema:name Department of Oncology, University College London Hospitals, London, UK
243 rdf:type schema:Organization
244 https://www.grid.ac/institutes/grid.470144.2 schema:alternateName Velindre Cancer Centre
245 schema:name Cardiff NCRI RTTQA group, Department of Medical Physics, Velindre Cancer Centre, Cardiff, UK
246 Pharmacy Department, Velindre Cancer Centre, Velindre NHS University Trust, Cardiff, UK
247 rdf:type schema:Organization
248 https://www.grid.ac/institutes/grid.4991.5 schema:alternateName University of Oxford
249 schema:name Centre for Statistics in Medicine, University of Oxford, Oxford, UK
250 Department of Oncology, University of Oxford, CRUK MRC Oxford Institute for Radiation Oncology, Oxford, UK
251 Oncology Clinical Trials Office, University of Oxford, Oxford, UK
252 rdf:type schema:Organization
253 https://www.grid.ac/institutes/grid.5600.3 schema:alternateName Cardiff University
254 schema:name Centre for Trials Research, Cardiff University, Cardiff, UK
255 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...